Membership

Nancy Brown is Chief Executive Officer of the American Heart Association. Under her leadership as CEO since 2008, the Association has become a global authority on cardiovascular and brain health, generating $1.2 billion annually to power its mission: to be a relentless force for a world of longer, healthier lives. 

Together with 35 million volunteers, supporters and staff across 100 countries, Nancy champions health and hope for everyone, everywhere. The Association funds groundbreaking research, advocates for the public’s health and provides critical resources to save and improve lives affected by cardiovascular disease and stroke. 

Highlights include:

• Investing more than $6.1 billion to accelerate scientific discoveries in cardiovascular and cerebrovascular care and drive innovation.
• Expanding the Association’s global leadership in resuscitation science and CPR/AED education and training, including launching the “Nation of Lifesavers” movement to empower everyone to save a life.
• Empowering women’s health through the Go Red for Women® movement, Research Goes Red registry and the Go Red for Women Venture Fund—the largest known dedicated women’s health venture fund in the U.S.
• Funding innovative science in brain health and advancing solutions to build lifelong cognitive skills and prevent brain disorders and diseases.
• Elevating heart and stroke quality improvement programs and registries in more than 3,000 hospitals and nearly 2,000 clinics across the U.S. and in 14 countries.
• Advocating for policies and legislation that support healthy communities and access to affordable care through the You’re The Cure grassroots network and Voices for Healthy Kids.
• Investing in and creating innovative commercial solutions through AHA Ventures, Cardeation Capital, and the Association’s Social Impact Funds that support entrepreneurial businesses and community leaders to create equitable, sustainable health solutions.
• Building a healthy, high-performing workforce by partnering with Fortune 500 CEOs, through the AHA CEO Roundtable, to improve the health and well-being of employees, families and communities.
• Leading an integrated approach to food science initiatives, including a multisector Health Care by Food initiative, and developing go-to-market solutions that improve health, food system sustainability and nutrition security.
• Defining cardio-kidney-metabolic syndrome for the first time and launching an initiative to provide treatment guidelines and solutions for the roughly 1 in 3 people affected in the U.S.
• Launching a world-class clinical research services enterprise to accelerate solutions using data science, registries, and real-life studies.

Dr. Victor J. Dzau, MD, is the President of the National Academy of Medicine (NAM), formerly the Institute of Medicine (IOM). In addition, he serves as Vice Chair of the National Research Council. Dr. Dzau is Chancellor Emeritus and James B. Duke Distinguished Professor of Medicine at Duke University and the past President and CEO of the Duke University Health System. Previously, Dr.Dzau was the Hersey Professor of Theory and Practice of Medicine and Chairman of Medicine at Harvard Medical School’s Brigham and Women’s Hospital, as well as Bloomfield Professor and Chairman of the Department of Medicine at Stanford University. 

Dr. Dzau is an internationally acclaimed physician scientist and leader whose work has improved health and medicine in the United States and globally. His seminal work in cardiovascular medicine and genetics laid the foundation for the development of the class of lifesaving drugs known as ACE inhibitors, used globally to treat hypertension and heart failure. Dr. Dzau pioneered gene therapy for vascular disease and was the first to introduce DNA decoy molecules in humans in vivo. His pioneering research in cardiac regeneration led to the Paracrine Hypothesis of stem cell action and his recent strategy of direct cardiac reprogramming using microRNA. He maintains an active NIH-funded research laboratory. 

Dr. Dzau is a leader in health and heath policy. At the NAM, he has led important initiatives such as Vital Directions for Health and Health Care, the Action Collaborative on Countering the US Opioid Epidemic, and the Action Collaborative on Clinician Well-Being and Resilience. Under his tenure, the NAM has advanced efforts to improve health equity and address racism throughout its programmatic activities, especially the Culture of Health Program. Most recently, the NAM launched a Grand Challenge in Climate Change and Human Health & Equity to reverse the negative effects of climate change on health and social equity by activating the entire biomedical community, communicating and educating the public about climate change and health, driving changes through research, innovation and policy, and leading bold action to decarbonize the health care sector.

Juan Camilo leads the advancement of a diverse portfolio of medicines and solutions that focus on improving the health of women and all patients. In this role, he contributes his strategic and dynamic perspective, overseeing and strengthening the organization’s scientific, medical and regulatory capabilities in support of its long-term mission.

Juan Camilo has over 20 years of experience in clinical research and development. Before joining Organon, he was the Chief Medical Officer of Myovant Sciences Inc., where he provided strategic direction and execution oversight to the global development and medical affairs teams. Previously, he was SVP of clinical development at Shionogi Inc., where he led the development of clinical strategy and provided execution oversight for late-stage development programs. Prior to Shionogi, he was the Executive Director of Clinical Research in Women’s Health at Merck and led the product development teams for all programs in contraception and women’s health. Earlier in his career, he practiced as an OB-GYN in university hospitals and in private practice.

Juan Camilo has an M.D. and post-graduate specialist training in obstetrics and gynecology from Colegio Mayor del Rosario in Bogota, Colombia.

Janet Foutty is a business leader, technologist, author, and frequent public speaker. She spent over three decades at Deloitte, culminating as CEO of Deloitte Consulting and later as Chair of Deloitte US, where she guided the firm through significant technology and business transformation. Recognized by Fortune, Forbes, Harvard Business Review, and The Wall Street Journal, Janet has been honored for her leadership and advocacy on issues of diversity, equity, inclusion, and innovation. 

Today, Janet applies her experience across three domains:

• Women’s Health: She is Senior Advisor to Women’s Health Access Matters (WHAM), serves as an advisor to Amboy Street Ventures, and chairs the nonprofit Bright Pink, advancing prevention and health equity for young women.
• Technology & Innovation: She serves on the boards of Insight Enterprises, Argonne National Laboratory, and Quiver Biosciences, and is an operating partner with Mudita Ventures.
• Leadership in Chicago: She serves on the boards of P33, a civic technology initiative advancing Chicago’s innovation economy, the Graham School at the University of Chicago, and The Chicago Network.

Janet spent the past academic year as a Leadership Fellow at the University of Chicago, furthering her commitment to scholarship, civic engagement, and the next generation of purpose-driven leaders. 

She holds a Bachelor of Science from Indiana University and an MBA in Finance from the Kelley School of Business at Indiana University, where she was inducted into the Academy of Alumni Fellows and recently served as the Poling Chair. She lives in Chicago with her husband, Kent, and is the proud parent of twin adult children

Dr. Jyoti Gupta is the President & CEO of Women’s Health & X-ray at GE HealthCare (NASDAQ: GEHC) where she is responsible for leading a $1B+ global business. Jyoti has spent her career in the MedTech sector spanning women’s health, ophthalmology, drug delivery and orthopedics across start-ups, mid- and large-cap organizations. 

Previously, Jyoti was the CEO of Volk Optical, a leading global eye-health company and subsidiary of Halma, Plc, a UK-based FTSE 100 company (LON: HLMA). At Volk, Jyoti successfully turned around a declining business to achieve record sales & profit by transforming the company from a legacy hardware business to a modern, connected device and digital health solutions organization focused on eradicating preventable blindness. Jyoti previously served as VP & General Manager of pre-filled syringes at Unilife, a drug-delivery device start-up that went public where she helped lead multiple capital raise rounds from individual and institutional investors, resulting in over $150M cash infusion into the company. Previously, she held roles at large corporations such as Becton Dickinson where she worked in strategic marketing of selfinjection drug-devices and started her career in clinical research at Medtronic working on the first metal-on-metal lumbar disc implant. 

Jyoti is known for her ability to set a clear and strong strategic direction, ability to scale businesses, and drive sustainable P&L growth. She is a strong advocate for advancing women’s health issues, spending time with state and federal lawmakers to raise awareness on the challenges faced by women and serves on Advamed’s Women’s Health Equity Initiative Subcommittee. 

Jyoti currently serves as a board member to start-up Eyesight Dx, is an advisor to start-up EyeCheq, and serves on the External Advisory Board at the School of Chemical & Biomolecular Engineering at Georgia Institute of Technology where she received her PhD. 

She has been recognized as Modern Healthcare’s Leading Women in 2025, Georgia Tech’s 40 under 40 in 2021, and Crain's Cleveland 40 under 40 in 2020. Jyoti has lived and studied in five different countries including the United Kingdom, United Arab, Emirates, India, Kuwait and the United States.

Shane Jacobson is the CEO of both the American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN). Jacobson is a dynamic, visionary leader who has dedicated his career to fueling nonprofit impact and driving growth. As CEO and alongside the ACS Board of Directors, he is charged with guiding both organizations – and their more than 3,000 team members and 1.3 million volunteers – toward a vision to end cancer as we know it, for everyone.

With more than two decades of nonprofit experience, including 15 years in nonprofit executive management, Jacobson has a history of leading organizations to achieve record-setting results and mission-driven outcomes. He comes to ACS most recently from the V Foundation for Cancer Research, where he has served as CEO since 2021 and led a team focused on accelerating game-changing research and funding top scientists.

During Jacobson's tenure at the V Foundation, revenue grew by 190 percent and grant-making by 275 percent. With a passion for connecting mission to high-impact opportunities, he elevated distinctive investments and fundraising in cancer research, including health disparity research and reinvestment strategies in the most promising ideas. To accelerate strategic objectives, Jacobson facilitated the V Foundation's most significant partnerships and charitable gifts in the organization's history, such as those with the Miami Dolphins, the University of Miami’s Sylvester Cancer Center, and the National Hockey League.

Jacobson previously served as president and CEO of the University of Vermont Foundation, where he led transformative fundraising campaigns, particularly in support of academic medicine and patient care.

Jacobson has worked with volunteer and staff leaders throughout his career to build audacious strategic plans, leading organizations to achieve groundbreaking results while enhancing culture, brand stature, and impact. At the V Foundation, he gained deep expertise in the power of early-stage cancer research to impact cancer and save lives. He also has experience harnessing the impact of advocacy to fuel change.

A native of Iowa, Jacobson received his M.Ed. in Educational Leadership and Policy and his B.A. in Communications Studies from Iowa State University. He also participated in the Management Development Program at Harvard University Graduate School of Education. He has served on numerous boards and committees, including the Cancer CEO Roundtable, the Association of Governing Boards' Council of Presidents, AGB Foundations Advisory Council, and the UVM President's Commission on Inclusive Excellence. He is also a member of the North Carolina Executive “Group of 50” and the CEO Advisory Board of the US Veterans Golf Association. 

Ms. Johnson founded Daré Bioscience Operations in 2015 and has served as President, CEO and a member of the Board of Directors since its inception and following its business combination with Cerulean Pharma in July 2017, when the Company was renamed Daré Bioscience. Ms. Johnson is a life sciences executive committed to advancing improvements in women’s healthcare. 

Previously, Ms. Johnson served as President of WomanCare Global Trading, a specialty pharmaceutical company in female reproductive healthcare with commercial product distribution in over 100 countries, from October of 2014 to May of 2015, and CFO and COO from July 2013 to October 2014. Ms. Johnson provided financial consulting services to the WomanCare Global family of companies, including the United Kingdom-based non-profit division, from November 2012 to July 2013. From 2002 until its sale in 2010, Ms. Johnson served as CFO of Cypress Bioscience, a publicly-traded pharmaceutical company, and in addition served as its COO from 2008 until its sale in 2010. Ms. Johnson began her career in the biotechnology industry as a research scientist with Baxter Healthcare, Hyland Division, working on their recombinant factor VIII program, and later held marketing and sales positions with Advanced Tissue Sciences and Clonetics Corporation. 

Ms. Johnson currently serves on the boards of directors of ATAI Life Sciences, a publicly-traded clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders; Biocom California as board chair elect; and the Clearity Foundation as past Board Chair. Additionally. Ms. Johnson serves on the Board of Advisors of Tulane University School of Science & Engineering.

Ms. Johnson has a Masters of International Management degree with honors from the American Graduate School of International Management (Thunderbird), a MSc in Biochemical Engineering from the University of London, University College London and a BSc in Biomedical Engineering from Tulane University, where she graduated magna cum laude.

Sara Rico is a Senior Customer Success Manager at Microsoft, where she leads initiatives within the Tech for Social Impact division. In her role, she empowers nonprofits and global health organizations to leverage Microsoft’s technology and data platforms to drive positive, community-centered outcomes. Passionate about innovation in women's health, Sara also serves as the Women’s Health Global Community Lead, where she advocates for advancements in femtech and digital health. She is a frequent speaker and moderator on topics such as patient empowerment, the value of data in healthcare, and the role of technology in education and social change. Known for her collaborative approach and dedication to inclusive innovation, Sara plays a key role in mentoring startups and building strong networks that bridge technology and impact-driven missions.

Stacey E. Rosen, MD is the Executive Director for Northwell’s Katz Institute for Women’s Health, the Partners Council Professor of Women’s Health and Professor of Cardiology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Rosen is a leading expert in women’s cardiovascular disease and oversees women's health services at Northwell with a focus on the elimination of healthcare disparities through comprehensive clinical programs, sex- and genderbased research, community partnerships and education. 

Dr. Rosen has been a practicing cardiologist for over 30 years. She co-authored the book, Heart Smarter for Women: Six Weeks to a Healthier Heart published in 2022 and co-produced the documentary “Ms. Diagnosed” which premiered at the Cinequest film festival in 2020. 

A longtime volunteer for the American Heart Association (AHA), Dr. Rosen serves as the AHA volunteer President 2025-2026. Dr. Rosen received the 2018 AHA Women in Cardiology Mentoring Award and in 2021, she received the AHA’s Physician of the Year Award. Dr. Rosen is the 2023 recipient of the WomenHeart Wenger Award for Excellence in Medical Advocacy and was named to Modern Healthcare’s 50 Most Influential Clinical Executives class of 2024. She received the 2025 American Medical Women’s Association (AMWA) Lila A. Wallis Women’s Health Award. 

Dr. Rosen graduated from the six-year medical program at Boston University School of Medicine and is a Fellow of the American College of Cardiology, the American College of Physicians, and the AHA.

Randi Seigel provides legal and strategic counsel to health care providers, emerging health tech and services companies, women’s health companies, insurers, and post-acute care providers. Randi brings substantial knowledge of complex health care regulations, including the HIPAA and state privacy laws, state licensure and scope of practice laws, telehealth, artificial intelligence, Medicare and Medicaid conditions of participation and billing, fraud and abuse laws, and other regulatory and enforcement matters. Randi’s deep understanding of the health care players— from commercial and government payors to providers—brings valuable insights to her clients to assist them as they develop and execute their strategic goals. Randi also supports her clients in structuring innovative payment arrangements, assessing the risks and regulatory impacts of complex transactions, and responding to government audits. 

During her tenure at Manatt, Randi has advised a broad range of health care stakeholders— including emerging companies, large health systems, and nonprofit organizations—on delivering care and information to women. She frequently speaks and publishes on the legal and regulatory issues surrounding reproductive health care. 

Randi came to Manatt from the Visiting Nurse Service of New York (VNSNY), where she served as associate general counsel and then as the vice president of compliance and regulatory affairs and the privacy officer. Prior to VNSNY, Randi was a health care associate at mid-sized law firm. Randi has been recognized as a top-ranked attorney in Chambers USA for Healthcare (New York) from 2022 to 2025 and has been consistently named a Next Generation Partner by Legal 500, earning Leading Partner status in 2025. She is also listed in The Best Lawyers in America (2021– 2026), was honored as a Law360 “Rising Star” in 2019.

She graduated magna cum laude from Washinton University in St. Louis, with double major in women’s studies and philosophy and cum laude from Benjamin N. Cardozo School of Law and has a certificate in Bioethics and Medical Humanities from Albert Einstein College of Medicine.

Deena’s investments span stages and sectors, and include women’s health, digital health infrastructure, health equity, foodtech, and fintech. Above all, she seeks out extraordinary, often underdog founders on a mission. Prior to Lux, Deena was a partner at GV (formerly Google Ventures), led product partnerships at Google for health, search, and AI/ML, and directed social impact investments at Google.org. Deena also served as a Presidential Management Fellow at the U.S. Department of State under Secretary Clinton, where she helped launch President Obama’s first Global Entrepreneurship Summit. 

Deena self-funded her undergraduate degree at Harvard (Social Studies and Near Eastern Languages & Civilizations) and MA at Georgetown through a variety of merit scholarships and side hustles, including co-founding and selling her first company while in college. She is a Lecturer in Management at the Stanford Graduate School of Business, a Board Director for the National Venture Capital Association, and a member of Kauffman Fellows, Aspen Finance Fellows, and The Council on Foreign Relations.

Deena is a frequent speaker and commentator and has been featured in print and television on Bloomberg, CNB and NBC, in print in the Wall Street Journal, Fortune, Forbes, Techcrunch, Marie Claire, STAT, and more, and has delivered keynote addresses at major industry conferences. She was named a “Top 30 Under 40 in Healthcare” by Business Insider and “Top Senior Woman to Watch in Venture Capital’ by the Wall Street Journal in 2021, “Top 50 in Digital Health” by Rock Health and 40 Under 40 by Fortune Magazine in 2022.

Trish Stroman is a leader in the BCG’s Health Care and Public Sector practices, with a focus on global public health. Since joining BCG in 2005, she has spent much of her career building and developing BCG’s social impact related activities. 

BCG’s global public health team shapes the investment strategies of the largest global health funders, advises clients on the optimal use of digital and technology in health, and works across 6 entities to develop innovative financing strategies. In her work with foundations, public-private partnerships, and public sector entities, Trish brings BCG's cutting-edge knowledge to bear, with an eye to customizing approaches in order to meet the needs of complex stakeholder environments. Her work is increasingly focused at the intersection of the public and private sectors as organizations need to collaborate in order to confront long-term intractable problems such as HIV/AIDS, malaria, and maternal health. 

Trish is the co-author of BCG’s recent perspective, “Improving Women’s Health Is a $100 BillionPlus Opportunity”. Before joining BCG, Trish was an internal consultant for the physician group at Kaiser Permanente.

Susan Sweeney is the executive vice president of Obesity and Related Conditions at Amgen. She is responsible for leading a cross-functional effort focused on advancing medicines in this area. Prior to this role, Sweeney held the position of senior vice president of Global Marketing and Access and Capabilities, where she was responsible for providing commercial leadership for Amgen products at all stages of the product lifecycle and for maximizing value across the portfolio. 

Sweeney joined Amgen in 2019 from Bristol-Myers Squibb, where she led commercial activities as President of U.S. Commercial. She joined BMS in 1995 and built a legacy of industry leadership over nearly 24 years, driving sustained growth for many of the company’s most successful medicines.

Sweeney earned an MPH from Columbia University Mailman School of Public Health and a BA from Gettysburg College

Dr. Kalahn Taylor-Clark, PhD, MPH is Vice President and Head of Social Impact and Sustainability at Merck, where she leads global strategy for ESG, sustainability, impact investing, and mission-aligned corporate initiatives. Her portfolio includes sustainability reporting, the Merck Foundation, Merck for Mothers, the Mectizan Donation Program, the U.S. Patient Assistance Program, employee giving efforts, and the Merck Impact Venture Fund. Through these efforts, she works to advance systems-level approaches to improve global access to health and sustainability outcomes. 

With nearly two decades of experience, Dr. Taylor-Clark has led innovative public health and equity strategies across industry, academia, nonprofits, and policy. Prior to joining Merck, she was VP and Head of Strategic Partnerships and Innovation at Myovant Sciences, where she led advocacy and equity-centered digital innovation strategies in women’s health and prostate cancer. 

From 2015 to 2021, she held senior leadership roles at Sanofi, starting as Associate Vice President of U.S. Cardiometabolic Public Affairs and Patient Advocacy, and later serving as Vice President and Global Head of Patient Centered Outcomes and Innovation. In this global role, she helped build and scale a new department focused on embedding patient insights into R&D.

Under her leadership, Sanofi became the first large pharma company to make 100 percent of late-stage clinical programs, indications, and trials patient-informed. 

Dr. Taylor-Clark has held academic appointments at Tufts University and George Mason University and now serves as adjunct faculty at Johns Hopkins University’s Carey Business School, teaching Healthcare Organizational Leadership and Inclusive Leadership. Earlier in her career, Dr. Taylor-Clark served as Director of Health Policy at the National Partnership for Women and Families and led patient centeredness initiatives at the Brookings Institution. 

Dr. Taylor-Clark holds a BA in International Relations from Tufts University, an MPH from Tufts School of Medicine, and a PhD in Health Policy from Harvard University. She serves on Tufts’ Board of Trustees and previously chaired the Board at the Prevention Institute. She lives in Arlington, VA with her son, Dashiell, and their two beloved dogs.